Organisation paid for research Program year 2025 Source: CMS Open Payments

Quality Clinical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$9,886,653

949 payments

Through program year 2025, Quality Clinical Research Inc is reported as receiving $9,886,653 in research payments, across 949 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $728,357 124
2024 Research $488,764 116
2023 Research $1,862,619 249
2022 Research $4,004,939 256
2021 Research $1,500,872 112
2020 Research $987,971 61
2019 Research $313,131 31

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $4,463,275 256 payments
  2. Pfizer Inc. $2,824,029 248 payments
  3. Bavarian Nordic A/S $1,040,106 118 payments
  4. Sanofi Pasteur Inc. $497,034 36 payments
  5. GlaxoSmithKline, LLC. $212,793 54 payments
  6. Ferring International Pharmascience Center US $199,188 15 payments
  7. AbbVie, Inc. $115,958 50 payments
  8. Ironwood Pharmaceuticals, Inc $100,058 47 payments
  9. Allergan Inc. $94,897 24 payments
  10. Ferring Pharmaceuticals AS $85,059 15 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $3,498,779 149 payments
  2. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $1,611,435 81 payments
  3. ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 $615,086 42 payments
  4. A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults $507,373 26 payments
  5. A Phase 12 Randomized Observerblind Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Varicella Zoster Virus in Healthy Individuals $480,069 43 payments
  6. A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older $357,378 16 payments
  7. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $289,452 35 payments
  8. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $252,322 21 payments
  9. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $244,376 29 payments
  10. A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults $233,786 26 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record